ArticleJournal of intensive medicine2025
The international, prospective CytOSorb
Article in Journal of intensive medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05146336 (CytOSorb TreatMent Of Critically Ill PatientS Registry), which is not on this map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
CytOSorb TreatMent Of Critically Ill PatientS Registry: International Registry on the Use of CytoSorb in the Critical Care Setting
Who cites it
9 citing papers in PubMed.
- The role of hemoadsorption in septic shock: toward a personalized approach.Critical care (London, England) · 2026Review
- CytoSorbBiomedicines · 2026Article
- Post-Transplant Sepsis After Liver Transplantation: Clinical Characteristics and Therapeutic Challenges.Journal of clinical medicine · 2026Review
- The international, prospective COSMOS (CytOSorb® TreatMent Of Critically Ill PatientS) Registry: results from the first 300 patients.Journal of anesthesia, analgesia and critical care · 2026Article
- Extracorporeal Cytokine Adsorption in Acute Cardiovascular Care: Pathophysiological Insights and Clinical Perspectives.Biomedicines · 2026Review
- Regulation of histones in thromboinflammation.Frontiers in immunology · 2026Review
- CytoSorb haemoadsorption in critically ill children: a multicentre observational study on feasibility, safety, and outcomes, the CYTOPED study.Annals of intensive care · 2026Article
- Hemoadsorption therapy in severe rhabdomyolysis: a report from the international, prospective COSMOS (CytOSorbRenal failure · 2025Observational
- CytoSorbBiomedicines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The CytOSorb Methods: Since July 2022, patients who were treated with CS as part of their intensive care treatment were enrolled from 16 sites in Germany, Italy, and Spain in the registry. After informed consent, real-world clinical data are systematically collected at multiple intervals, including 24 h before CS start, during CS treatment, and 24 h post-CS treatment, as well as at discharge from intensive care unit (ICU) and hospital discharge, and final follow-up on day 90. Vital status was assessed as ICU survival, 30-day survival, overall hospital survival, and 90-day survival. We compared details on the type of extracorporeal circuit used, device flow rate, anticoagulation regimen, vasopressor requirements, fluid balance, ratio of partial pressure of oxygen in arterial blood to the fraction of inspiratory oxygen concentration (P/F ratio), myoglobin in the rhabdomyolysis cohort and bilirubin in the liver failure cohort before and after CS treatment. Safety of the device was assessed by investigator-reported device-related adverse effects. Data were presented as either mean ± standard deviation or as median with interquartile range (IQR). Results: A total of 150 patients were enrolled, 23 patients did not have any data entry by the time of the data readout for this interim analysis conducted and therefore had to be excluded from the analysis (33 % female, mean age [59±17] years). CS indications included septic shock (57.6 %), cardiogenic shock (12.9 %), and rhabdomyolysis (10.6 %). CS was mainly integrated with renal replacement therapy (82.8 %). Median Acute Physiology and Chronic Health Evaluation II score was 23 (IQR: 17-29), Sequential Organ Failure Assessment score 12 (IQR: 9-15), and ICU stay 20 (IQR: 11-33) days. Median interleukin-6 decreased significantly from 862.4 (IQR: 142-97,457) pg/mL in the 24 h before CS treatment to 202.8 (IQR: 42-3247) pg/mL in the 24 h post-CS treatment ( Conclusions: The COSMOS registry highlights CS-associated improvements in lactate, creatinine, norepinephrine needs, fluid balance, and oxygenation. Mortality was favorable compared with risk-based predictions.Trial registration Clinicaltrials.gov Identifier: NCT05146336.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.